Biotech Balancing Act Survey Insights and Expectations

Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical Executive 2024-03, Vol.44 (3), p.20-21
1. Verfasser: Smyth, Chris
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 21
container_issue 3
container_start_page 20
container_title Pharmaceutical Executive
container_volume 44
creator Smyth, Chris
description Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organizations with a level of continuity across their development program that ad hoc contracting doesn't, facilitating integrated access to the necessary operational excellence, resources, and capacity. OPTIMIZING R&D TOGETHER As R&D spend rises across the board, from large pharma to emerging biotech companies, optimization will be a continued focus into 2024 and beyond.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_2973709975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2973709975</sourcerecordid><originalsourceid>FETCH-proquest_reports_29737099753</originalsourceid><addsrcrecordid>eNqNyrsKwjAUANAgCtbHPwT3wrVtGjNaUXTWwa2EGNtISWrurejfu_gBTmc5I5ZkawGpzMV1zBLIpEpLIWHKZogPACgKsUlYWblA1rS80p32xvmGbw3x8xBf9sNPHl3TEnLtb3z_7q0hTS54XLDJXXdolz_nbHXYX3bHtI_hOVikOto-RMI6UzKXoJQU-V_pCzjQNe0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2973709975</pqid></control><display><type>article</type><title>Biotech Balancing Act Survey Insights and Expectations</title><source>EBSCO Business Source Complete</source><creator>Smyth, Chris</creator><creatorcontrib>Smyth, Chris</creatorcontrib><description>Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&amp;D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organizations with a level of continuity across their development program that ad hoc contracting doesn't, facilitating integrated access to the necessary operational excellence, resources, and capacity. OPTIMIZING R&amp;D TOGETHER As R&amp;D spend rises across the board, from large pharma to emerging biotech companies, optimization will be a continued focus into 2024 and beyond.</description><identifier>ISSN: 0279-6570</identifier><identifier>EISSN: 2150-735X</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Alliances ; Alzheimer's disease ; Biotechnology industry ; Confidence ; Funding ; Innovations ; Oncology</subject><ispartof>Pharmaceutical Executive, 2024-03, Vol.44 (3), p.20-21</ispartof><rights>Copyright MultiMedia Healthcare Inc. Mar 2024</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,776,780,787</link.rule.ids></links><search><creatorcontrib>Smyth, Chris</creatorcontrib><title>Biotech Balancing Act Survey Insights and Expectations</title><title>Pharmaceutical Executive</title><description>Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&amp;D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organizations with a level of continuity across their development program that ad hoc contracting doesn't, facilitating integrated access to the necessary operational excellence, resources, and capacity. OPTIMIZING R&amp;D TOGETHER As R&amp;D spend rises across the board, from large pharma to emerging biotech companies, optimization will be a continued focus into 2024 and beyond.</description><subject>Alliances</subject><subject>Alzheimer's disease</subject><subject>Biotechnology industry</subject><subject>Confidence</subject><subject>Funding</subject><subject>Innovations</subject><subject>Oncology</subject><issn>0279-6570</issn><issn>2150-735X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNyrsKwjAUANAgCtbHPwT3wrVtGjNaUXTWwa2EGNtISWrurejfu_gBTmc5I5ZkawGpzMV1zBLIpEpLIWHKZogPACgKsUlYWblA1rS80p32xvmGbw3x8xBf9sNPHl3TEnLtb3z_7q0hTS54XLDJXXdolz_nbHXYX3bHtI_hOVikOto-RMI6UzKXoJQU-V_pCzjQNe0</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Smyth, Chris</creator><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20240301</creationdate><title>Biotech Balancing Act Survey Insights and Expectations</title><author>Smyth, Chris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_reports_29737099753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alliances</topic><topic>Alzheimer's disease</topic><topic>Biotechnology industry</topic><topic>Confidence</topic><topic>Funding</topic><topic>Innovations</topic><topic>Oncology</topic><toplevel>online_resources</toplevel><creatorcontrib>Smyth, Chris</creatorcontrib><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM global</collection><collection>Trade and Industry</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical Executive</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smyth, Chris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biotech Balancing Act Survey Insights and Expectations</atitle><jtitle>Pharmaceutical Executive</jtitle><date>2024-03-01</date><risdate>2024</risdate><volume>44</volume><issue>3</issue><spage>20</spage><epage>21</epage><pages>20-21</pages><issn>0279-6570</issn><eissn>2150-735X</eissn><abstract>Even with the macro-level obstacles, the biotech sector continues to grow across multiple metrics, with a backlog of emergent companies and R&amp;D spend rising across the board. The end-toend capabilities, global presence, and wide service offering of larger CROs provide specialized biotech organizations with a level of continuity across their development program that ad hoc contracting doesn't, facilitating integrated access to the necessary operational excellence, resources, and capacity. OPTIMIZING R&amp;D TOGETHER As R&amp;D spend rises across the board, from large pharma to emerging biotech companies, optimization will be a continued focus into 2024 and beyond.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 0279-6570
ispartof Pharmaceutical Executive, 2024-03, Vol.44 (3), p.20-21
issn 0279-6570
2150-735X
language eng
recordid cdi_proquest_reports_2973709975
source EBSCO Business Source Complete
subjects Alliances
Alzheimer's disease
Biotechnology industry
Confidence
Funding
Innovations
Oncology
title Biotech Balancing Act Survey Insights and Expectations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T04%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biotech%20Balancing%20Act%20Survey%20Insights%20and%20Expectations&rft.jtitle=Pharmaceutical%20Executive&rft.au=Smyth,%20Chris&rft.date=2024-03-01&rft.volume=44&rft.issue=3&rft.spage=20&rft.epage=21&rft.pages=20-21&rft.issn=0279-6570&rft.eissn=2150-735X&rft_id=info:doi/&rft_dat=%3Cproquest%3E2973709975%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2973709975&rft_id=info:pmid/&rfr_iscdi=true